SCHEMBL12529342

SCHEMBL12529342

COC(=O)c1nc2n(c(=O)c1C)CCC=C2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.36
HTR1A P08908 2/20 0.33
DRD2 P14416 2/20 0.33
HTR2A P28223 2/20 0.33
SMN1; SMN2 Q16637 5/20 0.32
KMT2A Q03164 3/20 0.32
RAB9A P51151 2/20 0.32
MAPT P10636 2/20 0.32
MEN1 O00255 1/20 0.32
NPC1 O15118 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
ALDH1A1 P00352 9/20 0.32
KDM4E B2RXH2 7/20 0.32
ATM Q13315 2/20 0.32
HPGD P15428 2/20 0.32
HSD17B10 Q99714 2/20 0.32
KDM5B Q9UGL1 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
POLB P06746 1/20 0.32
ADORA2A P29274 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1876028 0.86 NPSR1 (0.36) NPSR1HTR1ADRD2HTR2ASMN1; SMN2
SCHEMBL1750172 0.78 TSHR (0.38) NPSR1SMN1; SMN2KMT2AMAPTALDH1A1
SCHEMBL12529326 0.68 ALDH1A1 (0.36) NPSR1SMN1; SMN2KMT2ARAB9AMAPT
SCHEMBL12529340 0.68 MAPT (0.42) NPSR1SMN1; SMN2KMT2ARAB9AMAPT
SCHEMBL12529315 0.65 ALDH1A1 (0.36) NPSR1SMN1; SMN2KMT2ARAB9AMAPT
SCHEMBL17081012 0.64 HTR1A (0.53) HTR1ADRD2HTR2A
SCHEMBL1150933 0.64 NPSR1 (0.38) NPSR1SMN1; SMN2KMT2ARAB9AALDH1A1
SCHEMBL13696591 0.64 KDM4E (0.68) SMN1; SMN2KMT2ARAB9AMAPTNPC1
SCHEMBL12529331 0.63 ALDH1A1 (0.33) NPSR1SMN1; SMN2KMT2AMAPTMEN1
SCHEMBL13696593 0.62 KDM4E (0.51) SMN1; SMN2KMT2ARAB9AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968553-B2 e.g. N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; viricide in combination with other HIV/AIDS antivirals, immunomodulators, antibiotics or vaccines; AIDS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2011-06-28 US disclosed
US-7414045-B2 Substituted pyrimido[1,2-a]azepines useful as HIV integrase inhibitors ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2008-08-19 US disclosed
US-20080176869-A1 Tetrahydro-4H-pyrido[1,2-a] pyrimidines useful as HIV integrase inhibitors MSD ITALIA S.R.L. (IT) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176869-A1 Tetrahydro-4H-pyrido[1,2-a] pyrimidines useful as HIV integrase inhibitors TYMS, TYMP, DPYD NPSR1 4347/4885HTR1A 2609/4885DRD2 2829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.